We are pleased to announce Cardio-Oncology is now indexed in PubMed Central. The journal has passed the rigorous evaluation required for a journal to be included in this index. All articles published in Cardio-Oncology will now be archived and searchable through PMC and PubMed.
PubMed Central indexing
Aims and scope
The editorial mission of Cardio-Oncology is to advance the science and practice of this emerging field to find a balance between oncologic efficacy and reducing adverse cardiovascular effects through timely publication and dissemination of peer-reviewed research. As an open access, online journal Cardio-Oncology provides a high visibility platform for the publication of original research and expert reviews on the cardiovascular effects of cancer treatment. Read more here.
Articles
-
-
A virtual-hybrid approach to launching a cardio-oncology clinic during a pandemic
-
Book review: cancer and the heart
-
A case report: rapid progression of coronary atherosclerosis in a patient taking Targretin (Bexarotene)
-
Takotsubo syndrome induced by brachytherapy in a patient with endocervical adenocarcinoma
-
Management of atrial fibrillation in patients taking targeted cancer therapies
-
Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic
-
Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
-
Doxorubicin cardiotoxicity and target cells: a broader perspective
-
Breast cancer treatment-associated cardiovascular toxicity and effects of exercise countermeasures
About the society
Cardio-Oncology is the official journal of the International Cardio-Oncology Society (ICOS). The society brings together cardio-oncologists from around the world with the aim of reducing cardiovascular disease in cancer patients and thereby saving patients' lives. For more information about this important work, please visit the ICOS website.
Members of ICOS currently receive a 25% discount on their submissions. The discount should be requested during the submission process.
New submission type: Case reports
Cardio-Oncology now welcomes well-described reports of cases that include the following:
- Unreported or unusual side effects or adverse interactions involving medications.
- Unexpected or unusual presentations of a disease.
- New associations or variations in disease processes.
- Presentations, diagnoses and/or management of new and emerging diseases.
- An unexpected association between diseases or symptoms.
- An unexpected event in the course of observing or treating a patient.
- Findings that shed new light on the possible pathogenesis of a disease or an adverse effect.
Authors are encouraged to describe how the case report is rare or unusual as well as its educational and/or scientific merits in the covering letter that accompanies the submission of the manuscript.
Announcing the launch of In Review
Cardio-Oncology, in partnership with Research Square, is now offering In Review. Authors choosing this free optional service will be able to:
- Share their work with fellow researchers to read, comment on, and cite even before publication
- Showcase their work to funders and others with a citable DOI while it is still under review
- Track their manuscript - including seeing when reviewers are invited, and when reports are received
About the Editors
Steven Lipshultz, Editor-in-Chief
Steven E. Lipshultz, MD, FAAP, FAHA is the A. Conger Goodyear Professor and Chair of the Department of Pediatrics at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, The State University of New York; the Chief of Service of Pediatrics at Kaleida Health; the Medical Director of Pediatric Services Business Development at John R. Oishei Children’s Hospital; President of UBMD Pediatrics (University at Buffalo Pediatric Associates, Inc.); and a Consultant in Pediatrics and Cardio-Oncology for the Roswell Park Comprehensive Cancer Center.
Joseph Carver, Deputy Editor
Joseph Carver is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center.
Giorgio Minotti, Deputy Editor
Giorgio Minotti is Professor of Pharmacology, Head of Drug Sciences and Clinical Pharmacology, Chief of Clinical Trial Center, at the University Campus Bio-Medico of Rome. His research interests focus on pharmacokinetics, pharmacodynamics, and clinical correlates of anticancer drugs cardiovascular toxicity.
-
Affiliated with
-
Cardio-Oncology is affiliated with the International Cardio-Oncology Society (ICOS).
-
- Editorial Board
- Instructions for Editors
- Sign up for article alerts and news from this journal
Follow
Annual Journal Metrics
-
Speed
36 days to first decision for reviewed manuscripts only
36 days to first decision for all manuscripts
87 days from submission to acceptance
30 days from acceptance to publicationUsage
61,438 Downloads
214 Altmetric Mentions
On the blog
-
Looking beyond physical health for World Cancer Day 2020
24 January 2020
-
Breast Cancer Quiz 2019
30 September 2019
-
Sharing data for the benefit of children with cancer
09 September 2019
Institutional membership
Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).